Mayne Nicola, Keady Simon, Thacker Meera
Paediatric and Adolescent Services, University College London Hospitals NHS Foundation Trust, London, UK.
Intensive Crit Care Nurs. 2008 Feb;24(1):59-62. doi: 10.1016/j.iccn.2007.06.002. Epub 2007 Aug 14.
Tumour lysis syndrome (TLS) can be a life threatening complication of cancer therapy where cells undergo overwhelming lysis. The result is a pattern of metabolic abnormalities leading to acute renal failure and possible coagulopathy. Prophylactic pharmaceutical interventions can prevent this syndrome in almost all patients reducing possible admission to the intensive care unit. This article reviews the clinical efficacy, side effect profile, dosing and administration of rasburicase, an intravenous recombinant urate oxidase used in patients at risk of Tumour lysis syndrome due to a high tumour burden or where treatment is required. Rasburicase is an expensive but effective treatment option in the prevention and treatment of tumour lysis syndrome.
肿瘤溶解综合征（TLS）可能是癌症治疗中一种危及生命的并发症，在此过程中细胞会发生大量溶解。其结果是出现一系列代谢异常，导致急性肾衰竭以及可能的凝血病。预防性药物干预几乎可以在所有患者中预防该综合征，减少入住重症监护病房的可能性。本文综述了拉布立酶的临床疗效、副作用、剂量及用法，拉布立酶是一种静脉注射用重组尿酸氧化酶，用于因肿瘤负荷高或需要治疗而有肿瘤溶解综合征风险的患者。拉布立酶在预防和治疗肿瘤溶解综合征方面是一种昂贵但有效的治疗选择。
